State of Michigan Retirement System Has $6.04 Million Position in Biogen Inc. $BIIB

State of Michigan Retirement System cut its stake in Biogen Inc. (NASDAQ:BIIB) by 85.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,103 shares of the biotechnology company’s stock after selling 248,200 shares during the quarter. State of Michigan Retirement System’s holdings in Biogen were worth $6,038,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. CVA Family Office LLC increased its position in Biogen by 18.1% during the 3rd quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock worth $65,000 after buying an additional 71 shares during the period. TD Private Client Wealth LLC lifted its holdings in shares of Biogen by 22.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 76 shares during the period. CX Institutional lifted its stake in Biogen by 6.1% during the third quarter. CX Institutional now owns 1,453 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 83 shares during the last quarter. Rothschild Investment LLC lifted its position in shares of Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after buying an additional 88 shares during the last quarter. Finally, True Wealth Design LLC lifted its holdings in shares of Biogen by 62.9% in the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 90 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

Shares of BIIB opened at $193.81 on Tuesday. Biogen Inc. has a 12 month low of $110.04 and a 12 month high of $202.41. The stock has a 50 day moving average of $177.26 and a 200 day moving average of $157.48. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $28.43 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 1.70 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last released its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the previous year, the company earned $3.44 earnings per share. The company’s quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, sell-side analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on BIIB shares. Truist Financial increased their price target on Biogen from $190.00 to $193.00 and gave the company a “hold” rating in a research note on Monday. Stifel Nicolaus increased their target price on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research report on Friday. Guggenheim increased their price target on Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a report on Monday. HC Wainwright raised their price objective on shares of Biogen from $194.00 to $228.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Oppenheimer increased their price objective on shares of Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, January 30th. Thirteen research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $206.21.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 748 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total transaction of $134,116.40. Following the completion of the transaction, the insider owned 6,271 shares in the company, valued at approximately $1,124,390.30. This represents a 10.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.18% of the stock is owned by corporate insiders.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance: Biogen reported fourth‑quarter and FY results ahead of expectations, prompting analysts to raise forecasts and price targets — a direct earnings-driven positive catalyst. Biogen Posts Q4 Beat, Analysts Raise Price Targets
• Positive Sentiment: Regulatory progress for Leqembi: A biologics license application for a subcutaneous formulation of Leqembi was designated for priority review — this could expand prescribing convenience and bolster long‑term franchise value. Biologics License Application for Subcutaneous LEQEMBI Designated for Priority Review
• Positive Sentiment: Geographic expansion: Reports that China fast‑tracked at‑home use of Leqembi add another potential growth market for the Alzheimer’s franchise. Biogen stock to pop again? China fast-tracks Leqembi
• Positive Sentiment: Big analyst upgrades: RBC raised its price target to $233 (Outperform) and HC Wainwright raised its target to $228 (Buy), both signalling double‑digit upside from current levels and reflecting confidence in Leqembi and cash‑flow prospects. RBC Raises Price Target on Biogen to $233
• Neutral Sentiment: Mixed/neutral analyst stances: Several shops (Citigroup, Piper Sandler, Wedbush, Truist) nudged price targets higher but kept Neutral/Hold ratings, leaving investor guidance mixed. Analyst Price Target Moves (Citigroup, Piper, Wedbush, Truist)
• Negative Sentiment: Franchise pressure and execution risk: Analysis points to MS‑franchise weakness and near‑term growth limits, which keep some analysts cautious despite the Alzheimer’s upside. Biogen FY25 Earnings: Stable EPS Amid MS Franchise Pressure

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.